MPS Limited has informed the Exchange about the Transcript of the Earnings call inter-alia on the Audited Financial Results of the Company for the Fourth Quarter (Q4) and Financial Year ended 31 March 2026..
MPSLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
MPS Limited reported its most profitable year in FY'26 with revenue of INR 768 crores (+5.7% YoY), EBITDA of INR 236 crores (+11.8%), and record EPS of INR 102.11. Q4 standalone showed strong performance with EBITDA margin expanding to 32.9%. The company guided for FY'27 EBITDA to comfortably exceed INR 300 crores, implying ~21% CAGR from FY'24. Management confirmed the INR 1,500 crores revenue target for FY'28 remains intact. Key growth drivers include AI-first knowledge solutions across Research, Education (including Unbound Medicine acquisition), and Corporate Learning segments. The Unbound Medicine acquisition (closed Feb 9, 2026) contributed INR 11.78 crores in 50 days with EBITDA margin of ~18.5%. No final dividend was recommended for FY'26 as capital is being deployed for M&A.
The company delivered record profitability and margin expansion, with clear FY'27 guidance providing visibility. The decision to skip dividends while actively pursuing acquisitions signals a growth-focused capital allocation strategy. Strong EBITDA margin guidance of 30-35% for FY'27 indicates continued operating leverage.